Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 43 | 2024 | 3217 | 5.160 |
Why?
|
Kidney Neoplasms | 44 | 2024 | 4312 | 4.640 |
Why?
|
Carcinoma, Transitional Cell | 13 | 2024 | 800 | 3.720 |
Why?
|
Urinary Bladder Neoplasms | 15 | 2024 | 2276 | 2.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2024 | 11709 | 1.740 |
Why?
|
Urologic Neoplasms | 7 | 2021 | 320 | 1.650 |
Why?
|
Immunoconjugates | 4 | 2023 | 949 | 1.440 |
Why?
|
Urogenital Neoplasms | 2 | 2020 | 135 | 1.250 |
Why?
|
Penile Neoplasms | 2 | 2021 | 162 | 1.230 |
Why?
|
Anilides | 6 | 2022 | 409 | 1.130 |
Why?
|
Immunotherapy | 11 | 2024 | 4641 | 0.790 |
Why?
|
Urinary Tract | 1 | 2024 | 309 | 0.710 |
Why?
|
Camptothecin | 1 | 2023 | 588 | 0.690 |
Why?
|
Antibodies, Monoclonal | 6 | 2023 | 9160 | 0.650 |
Why?
|
Pyridines | 6 | 2022 | 2860 | 0.610 |
Why?
|
Nephrectomy | 3 | 2022 | 1016 | 0.590 |
Why?
|
Bone Diseases | 1 | 2020 | 419 | 0.550 |
Why?
|
Testicular Neoplasms | 2 | 2019 | 801 | 0.530 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2021 | 4023 | 0.460 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 494 | 0.450 |
Why?
|
Bone Density Conservation Agents | 1 | 2020 | 794 | 0.430 |
Why?
|
Radiotherapy | 1 | 2019 | 1504 | 0.410 |
Why?
|
Medical Oncology | 1 | 2023 | 2312 | 0.390 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2943 | 0.380 |
Why?
|
Neoplasm Metastasis | 9 | 2023 | 4901 | 0.360 |
Why?
|
Humans | 89 | 2024 | 758381 | 0.350 |
Why?
|
Arabinonucleosides | 1 | 2009 | 34 | 0.330 |
Why?
|
Adenine Nucleotides | 1 | 2009 | 111 | 0.330 |
Why?
|
Buttocks | 1 | 2009 | 111 | 0.320 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13591 | 0.310 |
Why?
|
Sarcoma | 1 | 2019 | 1785 | 0.310 |
Why?
|
Lymph Nodes | 1 | 2019 | 3485 | 0.300 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 223 | 0.290 |
Why?
|
Aged, 80 and over | 20 | 2024 | 58681 | 0.280 |
Why?
|
Neoplasm Staging | 7 | 2021 | 11152 | 0.280 |
Why?
|
Protein Kinase Inhibitors | 4 | 2023 | 5629 | 0.270 |
Why?
|
Aneurysm, False | 1 | 2009 | 254 | 0.270 |
Why?
|
Male | 52 | 2024 | 358742 | 0.270 |
Why?
|
Tissue and Organ Harvesting | 1 | 2009 | 373 | 0.260 |
Why?
|
Adenocarcinoma | 2 | 2022 | 6313 | 0.250 |
Why?
|
Androgen Antagonists | 3 | 2023 | 1442 | 0.250 |
Why?
|
Middle Aged | 38 | 2024 | 219560 | 0.250 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 381 | 0.250 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2009 | 638 | 0.250 |
Why?
|
Fatigue | 2 | 2022 | 1542 | 0.240 |
Why?
|
Rare Diseases | 2 | 2020 | 619 | 0.230 |
Why?
|
Cyclophosphamide | 4 | 2021 | 2218 | 0.230 |
Why?
|
Cell Adhesion Molecules | 2 | 2021 | 1600 | 0.230 |
Why?
|
Prostatic Neoplasms | 6 | 2023 | 11336 | 0.230 |
Why?
|
Radium | 1 | 2024 | 72 | 0.220 |
Why?
|
Aged | 33 | 2024 | 168217 | 0.220 |
Why?
|
Doxorubicin | 4 | 2021 | 2209 | 0.220 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2821 | 0.210 |
Why?
|
Cystectomy | 3 | 2024 | 697 | 0.210 |
Why?
|
Vinblastine | 2 | 2021 | 487 | 0.210 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 7985 | 0.210 |
Why?
|
Phenylthiohydantoin | 2 | 2022 | 204 | 0.200 |
Why?
|
Salvage Therapy | 1 | 2009 | 1268 | 0.200 |
Why?
|
Brain Neoplasms | 2 | 2022 | 8981 | 0.200 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2023 | 3480 | 0.190 |
Why?
|
Nutrition Disorders | 1 | 2022 | 205 | 0.190 |
Why?
|
Bone Marrow Cells | 1 | 2009 | 2414 | 0.190 |
Why?
|
Phenylurea Compounds | 1 | 2024 | 529 | 0.190 |
Why?
|
Benzoxazoles | 1 | 2022 | 89 | 0.190 |
Why?
|
Organoplatinum Compounds | 2 | 2019 | 405 | 0.190 |
Why?
|
Treatment Outcome | 15 | 2024 | 64379 | 0.190 |
Why?
|
Cisplatin | 3 | 2021 | 1645 | 0.180 |
Why?
|
Chorionic Gonadotropin | 1 | 2023 | 457 | 0.180 |
Why?
|
Methotrexate | 3 | 2023 | 1719 | 0.180 |
Why?
|
Platinum | 1 | 2022 | 218 | 0.180 |
Why?
|
Adult | 28 | 2024 | 219916 | 0.180 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2024 | 1503 | 0.180 |
Why?
|
Prognosis | 9 | 2022 | 29558 | 0.180 |
Why?
|
Georgia | 1 | 2020 | 190 | 0.170 |
Why?
|
Deoxycytidine | 2 | 2021 | 870 | 0.170 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 259 | 0.170 |
Why?
|
Genetic Counseling | 1 | 2023 | 624 | 0.170 |
Why?
|
5'-Nucleotidase | 1 | 2020 | 161 | 0.170 |
Why?
|
Endocrine System Diseases | 1 | 2021 | 249 | 0.170 |
Why?
|
Angiogenesis Inhibitors | 4 | 2023 | 2047 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 316 | 0.160 |
Why?
|
Quinolines | 1 | 2024 | 759 | 0.160 |
Why?
|
Retrospective Studies | 21 | 2024 | 80170 | 0.160 |
Why?
|
Nitriles | 2 | 2022 | 957 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 210 | 0.160 |
Why?
|
Kidney Pelvis | 1 | 2019 | 188 | 0.160 |
Why?
|
Thyroid Diseases | 1 | 2022 | 386 | 0.150 |
Why?
|
Benzamides | 2 | 2022 | 1368 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2022 | 8506 | 0.150 |
Why?
|
Female | 33 | 2024 | 390316 | 0.150 |
Why?
|
Combined Modality Therapy | 4 | 2022 | 8530 | 0.150 |
Why?
|
Leucovorin | 1 | 2019 | 641 | 0.140 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2021 | 617 | 0.140 |
Why?
|
Costs and Cost Analysis | 1 | 2023 | 1673 | 0.140 |
Why?
|
Viral Vaccines | 1 | 2022 | 596 | 0.140 |
Why?
|
Exanthema | 1 | 2021 | 504 | 0.140 |
Why?
|
Obesity | 1 | 2019 | 12870 | 0.140 |
Why?
|
Immunohistochemistry | 2 | 2019 | 11070 | 0.130 |
Why?
|
Quality of Life | 3 | 2023 | 13286 | 0.130 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2023 | 1927 | 0.130 |
Why?
|
Bayes Theorem | 1 | 2023 | 2322 | 0.130 |
Why?
|
Autoantibodies | 1 | 2024 | 2118 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1317 | 0.120 |
Why?
|
Molecular Targeted Therapy | 3 | 2024 | 2796 | 0.120 |
Why?
|
Neck | 1 | 2019 | 731 | 0.120 |
Why?
|
Fluorouracil | 1 | 2019 | 1631 | 0.120 |
Why?
|
Eligibility Determination | 1 | 2018 | 419 | 0.120 |
Why?
|
Tumor Burden | 1 | 2020 | 1893 | 0.120 |
Why?
|
Neutrophils | 4 | 2022 | 3765 | 0.110 |
Why?
|
Lymphocytes | 2 | 2022 | 2610 | 0.110 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3840 | 0.110 |
Why?
|
Oligopeptides | 1 | 2019 | 1185 | 0.110 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2024 | 4549 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1594 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2022 | 1530 | 0.110 |
Why?
|
Gastrointestinal Diseases | 1 | 2021 | 1185 | 0.110 |
Why?
|
Forecasting | 2 | 2019 | 2920 | 0.110 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2154 | 0.110 |
Why?
|
Breast Neoplasms, Male | 1 | 2014 | 221 | 0.100 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1840 | 0.100 |
Why?
|
Anemia | 1 | 2022 | 1504 | 0.100 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 748 | 0.100 |
Why?
|
Young Adult | 9 | 2021 | 58808 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2021 | 1585 | 0.100 |
Why?
|
Pyrazoles | 1 | 2022 | 1990 | 0.100 |
Why?
|
Prospective Studies | 4 | 2024 | 54136 | 0.090 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4158 | 0.090 |
Why?
|
Survival Rate | 3 | 2020 | 12721 | 0.090 |
Why?
|
Patient Selection | 2 | 2019 | 4244 | 0.090 |
Why?
|
Pyrimidines | 1 | 2022 | 3006 | 0.080 |
Why?
|
Carcinoma | 1 | 2021 | 2330 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1855 | 0.080 |
Why?
|
Idarubicin | 1 | 2009 | 59 | 0.080 |
Why?
|
Filgrastim | 1 | 2009 | 132 | 0.080 |
Why?
|
Mitoxantrone | 1 | 2009 | 148 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1926 | 0.080 |
Why?
|
Disease-Free Survival | 4 | 2021 | 6821 | 0.080 |
Why?
|
Patient Participation | 1 | 2018 | 1436 | 0.080 |
Why?
|
Biopsy | 2 | 2019 | 6768 | 0.080 |
Why?
|
Vidarabine | 1 | 2009 | 336 | 0.070 |
Why?
|
Drug Evaluation | 1 | 2009 | 638 | 0.070 |
Why?
|
Survival Analysis | 5 | 2021 | 10112 | 0.070 |
Why?
|
Etoposide | 1 | 2009 | 630 | 0.070 |
Why?
|
Boston | 1 | 2020 | 9304 | 0.070 |
Why?
|
Cytarabine | 1 | 2009 | 696 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2023 | 39060 | 0.070 |
Why?
|
Papillomavirus Infections | 1 | 2018 | 1612 | 0.070 |
Why?
|
Pain | 1 | 2022 | 5065 | 0.070 |
Why?
|
Cell Line, Tumor | 1 | 2023 | 16886 | 0.070 |
Why?
|
Vincristine | 1 | 2009 | 1038 | 0.070 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2009 | 629 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2021 | 3527 | 0.070 |
Why?
|
Disease Progression | 2 | 2020 | 13468 | 0.060 |
Why?
|
Genomics | 1 | 2021 | 5789 | 0.060 |
Why?
|
Dementia | 1 | 2019 | 2650 | 0.060 |
Why?
|
Neoplasm Invasiveness | 2 | 2024 | 3617 | 0.060 |
Why?
|
Logistic Models | 1 | 2019 | 13276 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2009 | 1829 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12951 | 0.060 |
Why?
|
Time Factors | 3 | 2021 | 39873 | 0.060 |
Why?
|
Androgens | 2 | 2023 | 1291 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6493 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5246 | 0.050 |
Why?
|
Remission Induction | 1 | 2009 | 2388 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5331 | 0.050 |
Why?
|
Jumonji Domain-Containing Histone Demethylases | 1 | 2024 | 171 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9273 | 0.050 |
Why?
|
Glutaminase | 1 | 2022 | 33 | 0.050 |
Why?
|
Mutation | 3 | 2022 | 29915 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7377 | 0.050 |
Why?
|
United States | 2 | 2020 | 72140 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2023 | 275 | 0.050 |
Why?
|
Dexamethasone | 1 | 2009 | 1927 | 0.050 |
Why?
|
Genealogy and Heraldry | 1 | 2021 | 29 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2014 | 10747 | 0.050 |
Why?
|
Body Mass Index | 1 | 2019 | 12876 | 0.050 |
Why?
|
Glutamates | 1 | 2022 | 389 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7403 | 0.050 |
Why?
|
Vaccinia virus | 1 | 2022 | 331 | 0.050 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2022 | 342 | 0.050 |
Why?
|
Androstenes | 1 | 2022 | 182 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2022 | 15638 | 0.040 |
Why?
|
Glutamine | 1 | 2022 | 575 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9405 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6520 | 0.040 |
Why?
|
Penetrance | 1 | 2021 | 388 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2021 | 370 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2022 | 3615 | 0.040 |
Why?
|
Urothelium | 1 | 2021 | 277 | 0.040 |
Why?
|
GPI-Linked Proteins | 1 | 2020 | 468 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 354 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 876 | 0.040 |
Why?
|
Reoperation | 1 | 2009 | 4282 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2023 | 798 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 557 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 596 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 895 | 0.040 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2024 | 1016 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 851 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2021 | 454 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 698 | 0.040 |
Why?
|
Tissue Extracts | 1 | 2017 | 140 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 778 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 733 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13245 | 0.040 |
Why?
|
Haemophilus influenzae | 1 | 1997 | 180 | 0.040 |
Why?
|
Muscle, Smooth | 1 | 2021 | 924 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2023 | 1147 | 0.030 |
Why?
|
Recurrence | 1 | 2009 | 8426 | 0.030 |
Why?
|
Hospital Costs | 1 | 2022 | 960 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1997 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2018 | 677 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20500 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1000 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 989 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1086 | 0.030 |
Why?
|
Polysaccharides, Bacterial | 1 | 1997 | 574 | 0.030 |
Why?
|
Urinary Bladder | 1 | 2021 | 1166 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 3993 | 0.030 |
Why?
|
Amyloidosis | 1 | 2001 | 817 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1613 | 0.030 |
Why?
|
Warfarin | 1 | 2022 | 1482 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2018 | 1593 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12440 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22030 | 0.030 |
Why?
|
Neutropenia | 1 | 2018 | 884 | 0.030 |
Why?
|
Creatinine | 1 | 2018 | 1892 | 0.030 |
Why?
|
Streptococcus pneumoniae | 1 | 1997 | 732 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36285 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2024 | 2531 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2021 | 2717 | 0.020 |
Why?
|
Animals | 2 | 2022 | 167777 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2009 | 5649 | 0.020 |
Why?
|
Hemorrhage | 1 | 2022 | 3400 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2021 | 2800 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2001 | 2083 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 1997 | 2693 | 0.020 |
Why?
|
Artifacts | 1 | 2018 | 1897 | 0.020 |
Why?
|
Cohort Studies | 3 | 2020 | 41252 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 12262 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 21017 | 0.020 |
Why?
|
Paclitaxel | 1 | 2014 | 1728 | 0.020 |
Why?
|
Anticoagulants | 1 | 2022 | 4778 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7590 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2024 | 7843 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4839 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5199 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5737 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2001 | 3755 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 1997 | 4540 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8554 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2022 | 11471 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 10146 | 0.020 |
Why?
|
Adolescent | 3 | 2021 | 87888 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9575 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 73806 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15225 | 0.010 |
Why?
|
Pulse Therapy, Drug | 1 | 2001 | 36 | 0.010 |
Why?
|
Serum Amyloid A Protein | 1 | 2001 | 127 | 0.010 |
Why?
|
Transcription Factors | 1 | 2021 | 12096 | 0.010 |
Why?
|
Depression | 1 | 2019 | 8057 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17768 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2001 | 1378 | 0.010 |
Why?
|
Cerebrospinal Fluid Proteins | 1 | 1979 | 72 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 42058 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23341 | 0.010 |
Why?
|
Neuromuscular Diseases | 1 | 1979 | 255 | 0.010 |
Why?
|
Bacterial Vaccines | 1 | 1997 | 401 | 0.010 |
Why?
|
Vaccines, Synthetic | 1 | 1997 | 617 | 0.010 |
Why?
|
Motor Neurons | 1 | 1979 | 864 | 0.010 |
Why?
|
Child | 1 | 2021 | 79813 | 0.010 |
Why?
|
Age Factors | 1 | 1979 | 18357 | 0.000 |
Why?
|